Drugs / VLA1555
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06973772 | Mar → Jul 2027 expected | chikungunya, dengue disease | Butantan Institute | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-14 | Valneva Austria GmbH | Regulatory Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country valneva.com ↗
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to its single-dose vaccine IXCHIQ® |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-14 | Valneva Austria GmbH | Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country valneva.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VLA1555 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06973772 ↗ |
| Modality | Vaccine | “Chikungunya (CHIKV) live attenuated vaccine (VLA1555)” NCT06973772 ↗ |
| Route | Intramuscular | “Route: Intramuscular” NCT06973772 ↗ |